Scancell Holdings (GB:SCLP) has released an update.
Scancell Holdings Plc, a developer of cancer immunotherapies, has announced the extension of the redemption dates for its convertible loan notes (CLNs) by two years, with the new dates set in August and November 2027. In a strategic move, the company will also redeem approximately £0.5m of the 3% CLNs in cash and defer yearly interest, improving cash flow in the medium term. Additionally, the terms now allow for the conversion of the 3% CLNs into ordinary shares at any time before maturity, maintaining the original conversion price.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
